BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37820746)

  • 1. Prolonged screening interval due to the COVID-19 pandemic and its association with tumor characteristics and treatment; a register-based study from BreastScreen Norway.
    Eijkelboom AH; Larsen M; Siesling S; Nygård JF; Hofvind S; de Munck L
    Prev Med; 2023 Oct; 175():107723. PubMed ID: 37820746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Participation and cancer detection after reminders versus ordinary invitations in BreastScreen Norway.
    Thy JE; Vigeland E; Larsen M; Hofvind S
    J Med Screen; 2022 Sep; 29(3):178-184. PubMed ID: 35502849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival among women diagnosed with screen-detected or interval breast cancer classified as true, minimal signs, or missed through an informed radiological review.
    Tsuruda KM; Hovda T; Bhargava S; Veierød MB; Hofvind S
    Eur Radiol; 2021 May; 31(5):2677-2686. PubMed ID: 33180162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal and non-fatal breast cancers in women targeted by BreastScreen Norway: a cohort study.
    Tsuruda KM; Hoff SR; Akslen LA; Hofvind S
    Br J Cancer; 2024 Jan; 130(1):99-107. PubMed ID: 38049556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of breast cancer by prior screening results among women participating in BreastScreen Norway.
    Lilleborge M; Falk RS; Russnes H; Sauer T; Ursin G; Hofvind S
    Cancer; 2019 Oct; 125(19):3330-3337. PubMed ID: 31206638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screen-detected and interval breast cancer after concordant and discordant interpretations in a population based screening program using independent double reading.
    Martiniussen MA; Sagstad S; Larsen M; Larsen ASF; Hovda T; Lee CI; Hofvind S
    Eur Radiol; 2022 Sep; 32(9):5974-5985. PubMed ID: 35364710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance measures among non-immigrants and immigrants attending BreastScreen Norway: a population-based screening programme.
    Bhargava S; Akslen LA; Bukholm IRK; Hofvind S
    Eur Radiol; 2019 Sep; 29(9):4833-4842. PubMed ID: 30762109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early screening outcomes among non-immigrants and immigrants targeted by BreastScreen Norway, 2010-2019.
    Thy JE; Bhargava S; Larsen M; Akslen LA; Hofvind S
    Scand J Public Health; 2023 May; 51(3):403-411. PubMed ID: 35361004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening outcome for consecutive examinations with digital breast tomosynthesis versus standard digital mammography in a population-based screening program.
    Hovda T; Brandal SHB; Sebuødegård S; Holen ÅS; Bjørndal H; Skaane P; Hofvind S
    Eur Radiol; 2019 Dec; 29(12):6991-6999. PubMed ID: 31187221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of assessment pathways after abnormal mammography screening in Denmark, Norway, and Spain.
    Jørgensen SF; Sagstad S; Louro J; Román M; Castells X; Hofvind S; Njor S
    Breast Cancer Res Treat; 2024 May; 205(1):135-145. PubMed ID: 38285110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-reported symptoms among participants in a population-based screening program.
    Larsen M; Lilleborge M; Vigeland E; Hofvind S
    Breast; 2020 Dec; 54():56-61. PubMed ID: 32927237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway: A population-based study.
    Eijkelboom AH; de Munck L; Larsen M; Bijlsma MJ; Tjan-Heijnen VCG; van Gils CH; Broeders MJM; Nygård JF; Lobbes MBI; Helsper CW; Pijnappel RM; Strobbe LJA; Wesseling J; Hofvind S; Siesling S;
    Cancer Epidemiol; 2023 Dec; 87():102481. PubMed ID: 37897970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interval Breast Cancer Rates and Histopathologic Tumor Characteristics after False-Positive Findings at Mammography in a Population-based Screening Program.
    Hofvind S; Sagstad S; Sebuødegård S; Chen Y; Roman M; Lee CI
    Radiology; 2018 Apr; 287(1):58-67. PubMed ID: 29239711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway.
    Hovda T; Holen ÅS; Lång K; Albertsen JL; Bjørndal H; Brandal SHB; Sahlberg KK; Skaane P; Suhrke P; Hofvind S
    Radiology; 2020 Feb; 294(2):256-264. PubMed ID: 31821118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nonparticipation at previous screening rounds on the characteristics of screen-detected breast cancers.
    Duijm LEM; Broeders MJM; Setz-Pels W; van Breest Smallenburg V; van Beek HC; Donkers-van Rossum AB; Slob MJ; Kuipers TP; Mann RM; Voogd AC
    Eur J Radiol; 2022 Sep; 154():110391. PubMed ID: 35679699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammographic changes resulting from benign breast surgery impair breast cancer detection at screening mammography.
    van Breest Smallenburg V; Duijm LE; Voogd AC; Jansen FH; Louwman MW
    Eur J Cancer; 2012 Sep; 48(14):2097-103. PubMed ID: 22513229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
    Hofvind S; Holen ÅS; Aase HS; Houssami N; Sebuødegård S; Moger TA; Haldorsen IS; Akslen LA
    Lancet Oncol; 2019 Jun; 20(6):795-805. PubMed ID: 31078459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic.
    Eijkelboom AH; de Munck L; Lobbes MBI; van Gils CH; Wesseling J; Westenend PJ; Guerrero Paez C; Pijnappel RM; Verkooijen HM; Broeders MJM; Siesling S;
    Prev Med; 2021 Oct; 151():106602. PubMed ID: 34217417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts.
    Román M; Hofvind S; von Euler-Chelpin M; Castells X
    Br J Cancer; 2019 Jan; 120(2):269-275. PubMed ID: 30563993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer.
    Strand F; Humphreys K; Eriksson M; Li J; Andersson TM; Törnberg S; Azavedo E; Shepherd J; Hall P; Czene K
    Int J Cancer; 2017 Jan; 140(1):34-40. PubMed ID: 27615710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.